Business Context and Reporting Period
This Form 8-K Current Report was filed by Cytosorbents Corp (Nasdaq: CTSO) on August 28, 2023. The report addresses a material change in executive leadership under Item 5.02.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of CFO: Alexander D'Amico, who was appointed Chief Financial Officer effective August 7, 2023, mutually agreed to terminate his employment with the Company on August 28, 2023.
- Termination Agreement: The Company and Mr. D'Amico entered into a Mutual Termination and Release Agreement, which includes customary non-disparagement and release provisions.
- Interim Leadership: Ms. Kathleen Bloch will continue to serve as the Interim Chief Financial Officer under her existing consulting arrangement.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, or specific risk factors beyond the immediate impact of the executive departure. The report notes the execution of a press release dated September 1, 2023, as an exhibit.
Investor Verification Checklist
- Verify the terms of the Mutual Termination and Release Agreement regarding any severance or compensation owed to the departing CFO.
- Confirm the duration and scope of Ms. Kathleen Bloch's role as Interim CFO.
- Review the Company's press release (Exhibit 99.1) for additional context on the leadership transition.
- Monitor future filings for the appointment of a permanent Chief Financial Officer.